Production is oriented to the neutraceutical and pharmaceutical industries, and all products meet common American and European quality standards. The plant was built to maximize operating efficiency through many passive design features. These features are an important factor in keeping operating costs low without compromising quality. The plant was also designed to be expandable. Extra production units can be brought on-line quickly as demand increases.
Additional capacity is available for custom fermentation production.
Varsal uses amino acids produced in this facility to make derivatives for pharmaceutical intermediates. This business unit is growing rapidly for Varsal as the use of amino acids for chiral applications increases. The derivative product line utilizes a number of proprietary technologies to offer competitively priced, high quality products at full-scale production levels.